Aglatimagene besadenovec

Phase 3Gene therapy

Aglatimagene besadenovec is one of 112 biologic programs targeting Pancreatic Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

111

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic AdenocarcinomaActive, not recruiting

Prostate CancerActive, not recruiting

Non-Small Cell Lung CarcinomaRecruiting

Pancreatic AdenocarcinomaPhase 2

Active, not recruiting

Prostate CancerPhase 2

Active, not recruiting

Non-Small Cell Lung CarcinomaPhase 3

Recruiting

Competition

Competitive Landscape

1399 competitors in Prostate Cancer

#DrugCompanyPhaseTrials

Aglatimagene besadenovec

CCandel Therapeutics, Inc.

Phase 3

3 2

Mekinist

Novartis

Preclinical

3 3

Trexall

Alnylam Pharmaceuticals

Preclinical

—4

Ranexa

MMenarini International Operations Luxembourg SA

Preclinical

1 5

Duragesic

CCephalon

Preclinical

1 6

Prednisone/prednisolone

Roche

Preclinical

3 7

Triptorelin Pamoate

Ipsen

Preclinical

2 8

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

—9

Ifex

BBaxter Healthcare Corporation

Preclinical

—10

Naropin

FFresenius Kabi Oncology Ltd.

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 2Recruiting

Prostate Cancer

NCT07332000

Q4 2026

Phase 2Active, not recruiting

Prostate Cancer

NCT02768363

Phase 2Active, not recruiting

Immune Checkpoint Inhibitor

NCT04495153

Q4 2030

Phase 3Active, not recruiting

Prostate Cancer

NCT01436968

Q4 2031

Phase 3Recruiting

Non-Small Cell Lung Carcinoma

NCT07660094

Clinical

Trials by Indication[1]

Prostate Cancer3 trials

Phase 3 Study of ProstAtak® Immunotherapy With Standard Radiation Therapy for Localized Prostate Cancer

Active, not recruiting·CCandel Therapeutics, Inc.·Phase 3·NCT01436968·711 enrolled

A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec

Recruiting·CCandel Therapeutics, Inc.·Phase 2·NCT07332000·45 enrolled

Randomized Controlled Trial of CAN-2409 Immunotherapy During Active Surveillance for Prostate Cancer (ULYSSES)

Active, not recruiting·CCandel Therapeutics, Inc.·Phase 2·NCT02768363·187 enrolled

Pancreatic Adenocarcinoma1 trial

Neoadjuvant CAN-2409 in Combination With Chemoradiation or SBRT for Borderline Resectable Pancreatic Adenocarcinoma

Active, not recruiting·CCandel Therapeutics, Inc.·Phase 2·NCT02446093·54 enrolled

Immune Checkpoint Inhibitor1 trial

CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC

Active, not recruiting·CCandel Therapeutics, Inc.·Phase 2·NCT04495153·90 enrolled

Non-Small Cell Lung Carcinoma1 trial

A Phase 3, Multicenter, Randomized, Controlled, Open-Label Clinical Trial of Aglatimagene Besadenovec (CAN-2409) Plus Prodrug and Pembrolizumab Versus Docetaxel for Stage IV Non-Squamous Non-Small Cell Lung Cancer Progressing on Pembrolizumab-based Treatment

Recruiting·CCandel Therapeutics, Inc.·Phase 3·NCT07660094·500 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Aglatimagene besadenovec. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Aglatimagene besadenovec compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Aglatimagene besadenovec. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Candel Therapeutics, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Gene therapy[2]
Highest Phase: Phase 3[1]
Company: CCandel Therapeutics, Inc.

Aglatimagene besadenovec

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q4 2030

Q4 2031

Trials by Indication[1]

Prostate Cancer3 trials

Pancreatic Adenocarcinoma1 trial

Immune Checkpoint Inhibitor1 trial

Non-Small Cell Lung Carcinoma1 trial

References

Drug Info

Quick Facts

Related News